25 Results

People

  1. Abdel-Wahab
    Abdel-Wahab
  2. Dogan
    Dogan
  3. Levine
    Levine
  4. Zelenetz
    Zelenetz
  5. Intlekofer
    Intlekofer
  6. Mato
    Mato
  7. Palomba
    Palomba
  8. Roeker
    Roeker
  9. Van Den Brink
    Van Den Brink
  10. Rampal
    Rampal

Groups

  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Executive Committee, Center for Hematologic Malignancies (25)
  4. GSK Faculty (25)
  5. Hematologic Malignancies, Division of (25)
  6. Human Oncology and Pathogenesis Program (25)
  7. Lymphoma (25)
  8. Tow Center for Developmental Oncology (TCDO) (25)
  9. Adult Leukemia (23)
  10. Hematologic Malignancies Research (11)
  1. "Omar Abdel-Wahab"
  2. "Lymphoma"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (9)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Executive Committee, Center for Hematologic Malignancies (25)
  4. GSK Faculty (25)
  5. Hematologic Malignancies, Division of (25)
  6. Human Oncology and Pathogenesis Program (25)

More Groups

People
  1. Omar Abdel-Wahab (25)
  2. Ahmet Dogan (14)
  3. Ross Levine (14)
  4. Andrew Zelenetz (12)
  5. Andrew Intlekofer (11)
  6. Anthony Mato (9)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (3)
  4. 2021 (4)
  5. 2020 (1)
  6. 2019 (2)

More Years

Publications
  1. Blood (12)
  2. Cancer Research (1)
  3. Hematological Oncology (1)
  4. Journal of Clinical Oncology (1)
  5. Laboratory Investigation (1)
  6. Lancet (1)

More Publications

Publishers
  1. American Society of Hematology (12)
  2. Nature Publishing Group (4)
  3. Elsevier Science, Inc. (2)
  4. American Association for Cancer Research (1)
  5. American Association for the Advancement of Science (1)
  6. American Society of Clinical Oncology (1)

More Publishers

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
    Journal Article

    Montoya, S.; Bourcier, J.; Noviski, M.; Lu, H.; Thompson, M. C.; Chirino, A.; Jahn, J.; Sondhi, A. K.; Gajewski, S.; Tan, Y. S.; more...
    Science (2024)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
    Journal Article

    Ptashkin, R. N.; Ewalt, M. D.; Jayakumaran, G.; Kiecka, I.; Bowman, A. S.; Yao, J. J.; Casanova, J.; Lin, Y. T. D.; Petrova-Drus, K.; Mohanty, A. S.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors
    Journal Article

    Wang, E.; Mi, X.; Thompson, M. C.; Montoya, S.; Notti, R. Q.; Afaghani, J.; Durham, B. H.; Penson, A.; Witkowski, M. T.; Lu, S. X.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save